Abstract
Background Few studies have investigated the joint effects of sleep traits on the risk of acute myocardial infarction (AMI). No studies have used factorial Mendelian randomization (MR) which may reduce confounding, reverse causation and measurement error. Thus, it is prudent to study joint effects using robust methods to propose sleep-targeted interventions which lower the risk of AMI.
Objective To investigate the causal interplay between combinations of two sleep traits (including insomnia symptoms, sleep duration or chronotype) on the risk of AMI using factorial MR.
Methods Genetic risk scores for each sleep trait were dichotomized at their median in UK Biobank (UKBB) and the second survey of the Trøndelag Health Study (HUNT2). A combination of two sleep traits constituting 4 groups were analysed to estimate the risk of AMI in each group using a 2×2 factorial MR design.
Results In UKBB, participants with high genetic risk for both insomnia symptoms and short sleep had the highest risk of AMI (HR 1.10; 95% CI 1.03, 1.18), although there was no evidence of any relative excess risk due to interaction (RERI 0.03; 95% CI -0.07, 0.12). These estimates were less precise in HUNT2 (HR 1.02; 95% CI 0.93, 1.13), possibly due to weak instruments. Participants with high genetic risk for both a morning chronotype and insomnia symptoms (HR 1.09; 95% CI 1.03, 1.17); and a morning chronotype and short sleep (HR 1.11; 95% CI 1.04, 1.19) had the highest risk of AMI in UKBB, although there was no evidence of any relative excess risk due to interaction (RERI 0.03; 95% CI -0.06, 0.12; and RERI 0.05; 95% CI -0.05, 0.14, respectively). Chronotype was not available in HUNT2.
Conclusions All combinations of sleep traits increased the risk of AMI except those with long sleep, but the risk from these combinations did not exceed the additive risk from the individual sleep traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was made possible with the financial support from Nasjonalforeningen for folkehelsen (The National Association for Public Health) in Norway, having project ID 19479.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethical approval from the National Health Service (NHS) Research Ethics Service (reference number 11/NW/0382). The HUNT Study was approved by the Data Inspectorate of Norway and recommended by the Regional Committee for Ethics in Medical Research (REK; reference number 152/95/AH/JGE). The ethical approval for conducting this study was also obtained from the Regional Committee for Ethics in Medical Research (REK nord; reference number 2020/47206).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.